Span Divergent Limited-Financial Results for the quarter end June 30, 2026

Span Divergent Ltd. (Formerly Span Diagnostics Ltd.) 9th Floor, Rajhans Bonista, Behind Ram Chowk, Ghod Dod Road, Surat - 395 007, Gujarat, India Phone: +91 261 266 32 32 E-Mail: contact@span.in Date: August 11, 2026 Listing Compliance Department Bombay Stock Exchange Limited Phiroze Jeejeebhoy Tower, 25th Floor Dalal Street, Mumbai – 400 001 Scrip Code: 524727 Subject: Submission of Un-audited Financial Results (Consolidated & Standalone) of the Company for the First Quarter and Three Months ended June 30, 2026. Listing Regulation: Regulation 33 & all other applicable Regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time. Dear Sir/Madam, Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to forward herewith the Unaudited Financial Results of the Company, comprising both the Standalone Financial Results and the Consolidated Financial Results, for first quarter and three months ended June 30, 2026, along with the Limited Review Reports issued by the Statutory Auditors thereon. The aforesaid financial results were approved by the Board of Directors at its meeting held on Tuesday, August 11, 2026. The Board meeting commenced at 11:15 (IST) and concluded at 16:30 (IST). The same is available on the website of the Company at www.span.in. You are therefore requested to take the above information on records. Thanking You. Yours faithfully, For Span Divergent Limited Viral Desai Managing Director DIN 00029219 Encl: As above Span Divergent Limited (Formerly known Span Diagnostics Limited) Regd.Office : 9th Floor,902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007 CIN:L74999GJ1980PLC003710 Website: www.span.in Statement of unaudited Financial Result for the quarter ended June 30, 2026. (Rs in Lakhs) Standalone Results Three Months Year ended 31 Sr. No. Particulars Quarter ended Quarter ended Quarter ended March 2026 30 June 2026 31 March 2026 30 June 2025 Unaudited Unaudited Unaudited Audited 1 Income from operations Other Operating Income 13.45 35.66 38.45 146.64 Other income 17.38 12.25 26.48 75.78 Total income 30.83 47.91 64.93 222.42 2 Expenses Employee benefit expense 26.39 36.39 26.92 122.76 Finance costs 0.42 0.46 - 2.16 Depreciation and amortisation expense 5.75 6.53 6.28 25.80 Other expenses 14.00 8.58 7.99 40.24 Total expenses 46.56 51.96 41.19 190.96 Profit / (Loss) before exceptional items and tax (1-2) (15.73) (4.05) 23.74 31.46 Exceptional items (13.20) (7.60) (19.00) (41.10) Profit/(Loss) before tax (3-4) (2.53) 3.55 42.74 72.56 Tax expense: - Current tax - - - - - Deferred tax 1.69 (1.66) 1.07 (0.08) 7 Profit/(Loss) forthe period after tax (5-6) (4.22) 5.21 41.67 72.64 8 Other comprehensive income Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities) (0.63) 5.84 (0.18) 5.29 Incometax relating to items that will not be reclassified to Profit or Loss 0.14 (1.36) 0.05 (1.21) 9 Total comprehensive income for the year (7+8) (4.71) 9.69 41.54 76.72 Paid-up equity share capital (Face value of Rs. 10/- each) 726.32 726.32 546.17 726.32 11. |Other Equity : 5 - 3,396.15 12 |Weightage Average Noof Paid-up Equity Shares 72,63,228 54,81,489 54,61,747 54,81,489 Earnings per equity share for profit from operation attributable to ownersof the entity: 13 _|Basic earnings per share (0.06) 0.09 0.76 1.33 14 Diluted earnings pershare (0.06) 0.09 0.76 (E33 Note: - The above results have been reviewed by the Audit Committee and approved by the BoardofDirectors at their meeting held on August 11, 2026. Other Operating Income comprisesof Interest on fluctuating capital provided by the Companyto its LLP subsidiaries and managementfees income which is based on the revenue earnedby subsidiaries during the quarter. In case of subsidiary: a) Aranya Consulting and Biotech LLP, w.e.f May19, 2026 ( Formerly, Aranya Agri Biotech LLP) had accumulated lossesof Rs. 1494 Lakhs till March 31 2026 andloss of Rs.0.69 Lakhs in the current year, up to June 30, 2026. (b) Biospan Scientific LLP had accumulatedlosses of Rs.157 Lakhs as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 183 Lakhs were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepa ire td on going concern basis as Managementis exploring the possibilities to revive the LLP on its ownorby entering in to business tie-ups and endeavours to be able to establish profitable operation. (c) Biospan Contamination Control Solutions Pvt. Ltd had accumulatedlosses of Rs.742 Lakhstill June 30, 2026. As on that date the subsidiary Company’s total liabilities exceeded its total assets by Rs. 752 Lakhs. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive in short term horizon. Previous pericds figures have been regrouped and rearranged wherevernecessary. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards)(Amendment) Rules, 2016. The abovefinancial results are also available on the Company's website www.span.in and BSE Limited's website www.bseindia.com. For Span Divergent Limited Place : Surat Viral Desai Date : August 11, 2026 Managing Director DIN: 00029219 B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC — APPLICABLE (ANNEXURE ATTACHED C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES — NOT APPLICABLE, NO DEFAULT D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) —- NOT APPLICABLE E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONGWITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - NOT APPLICABLE AION syseuoy L9Joy “ONSSI SUIPsOIIF yalqo s}dalgo UOHRIUG 00°0 00°0 00°0 paleis junowy aquaydde GaldVTVN0 J9}1eNb A/UONRIAIG SpseMO} “ANSSI SUNIL SUYe'T SUYPT spuny pasynn 96 PaZITAN 00'0S 9C°6T TVILNANaA “CLE aq aad Aue SYR] payipoyy Suoneoo][e 00°0 00°0 00'0 “ANSST pO'LT[z SUxPT SUAP'T SUNT JO SLHOTY [euro UonRIOI[y 0000S 00'0S 9€°6T JuNowr ‘OLA aja “ANSST ‘saffo 9[QU} pozijynun LNAWAO JUSLUJO][B fo OLTE 40 sayjay Nd Td JO SUIMOT[OJ Aue oy] jt pasojasip AO BBC pow “3°! IY} valqo VN VN VN ‘spsedoid ‘snjoadsosd SAAD anNss] SUPT UI SNOILOLILSNI OTOT 40 AyjoUulsi410 9T0T anssi ‘a1 OUd juss19AIq “ST OE aiqeorddy aiqeorddy aiqeoiddy ‘UONBIADp poyipoy pasiv4 [PNUsLIfJo1d 6LS “OE aqvorddejon SoM WOU ueds YL) UNI Suns 10N| ON) I0N| 10N| & jenussajosd uaag JOYM Juawngzop + 4 4 U90q NOLLVIAVA pasiva SBY SyUOW jeuoneiodQ oy} aavy JsuIMsD sursios € JO spunf spuny BJOSUIII} slappoyaivys 9194) Z- ) Sv punf YO Jo 7 UONSI[IN ay) pazyyn ayy pasivl IATA Ayyend MIIAIT A1OUBAUT yoiym ul UOHRZYHN ay} 34} 0} NOLLVIAAG SpUNY ULasuLYD Aq PUL pue UL sof Ayonjov ul JO 0} uOHeIIBA 1d}JU paste. yalqo (NOY) SuluolssimWoD) pasiafas arquoydde ISN / UONLLA sasodind NO UOnRLIeA Popud ji UL UENSAN paaouddesem jeaouddy Id}JIWIWIOD JA [Showing first 8,000 characters — download PDF for full document]